Cabergoline for Inhibition of Lactation
(eLISTA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if cabergoline, a medication, can prevent breast pain and milk leakage after a second-trimester abortion or fetal loss between 16 and 20 weeks. Previous studies have shown its effectiveness in later stages, and researchers now seek to assess its efficacy earlier. Participants will receive either cabergoline or a placebo to compare outcomes. Suitable candidates include English or Spanish-speaking pregnant individuals who have experienced an abortion or are managing a fetal loss between 16 and 20 weeks of pregnancy. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant early-stage findings.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently receiving dopamine agonist or antagonist therapy for other conditions. If you have uncontrolled hypertension requiring more than one medication, you may also be excluded.
Is there any evidence suggesting that cabergoline is likely to be safe for humans?
Studies have shown that cabergoline is generally well tolerated for stopping breast milk production. Some people report mild side effects, such as dizziness, headache, nausea, and vomiting. These side effects are usually not severe and are mostly manageable, often not lasting long.
It's important to note that while cabergoline is safely used in many cases, it should not be used to stop breast milk production immediately after childbirth due to the risk of serious side effects. In this study, researchers are exploring cabergoline for a different purpose, and past research suggests it has a promising safety profile.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for lactation inhibition, which often involve hormonal therapies like estrogen or bromocriptine, cabergoline works differently by directly targeting dopamine receptors to reduce prolactin levels. Researchers are excited about cabergoline because it can be taken as a single oral dose, offering a convenient and potentially faster-acting option compared to treatments that require multiple doses over time. This specificity in action and ease of administration could lead to fewer side effects and improved patient compliance, making it a promising alternative for those needing lactation suppression.
What evidence suggests that cabergoline might be an effective treatment for lactation inhibition?
Research has shown that cabergoline, which participants in this trial may receive, effectively stops milk production. In past cases, 78% to 100% of patients using cabergoline successfully prevented milk production. One study found that cabergoline also helped prevent breast pain and swelling after a second-trimester abortion or loss. Compared to other treatments like bromocriptine, cabergoline works just as well but with fewer side effects. This suggests that cabergoline could help reduce breast pain and milk leakage after an early second-trimester abortion.36789
Are You a Good Fit for This Trial?
This trial is for pregnant individuals aged 18 or older who are undergoing an early second-trimester abortion or managing a fetal demise at 16-20 weeks gestation. Participants must have access to a smartphone, be able to understand English or Spanish, and willing to follow study procedures. Those with uncontrolled high blood pressure, prior mastectomy, current breastfeeding, dopamine therapy use, heart valve disorders, or fibrotic disorders cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either cabergoline 1 mg or placebo orally on the day of the procedure
Follow-up
Participants complete surveys to assess symptoms and side-effects at baseline and on Day 2, 4, 7, and 14 after the procedure
What Are the Treatments Tested in This Trial?
Interventions
- Cabergoline
Trial Overview
The trial is testing if Cabergoline can prevent breast pain and milk production after an early second-trimester loss compared to a placebo. It builds on previous findings that the drug helps later in pregnancy by seeing if it's effective earlier on.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
After the completion of the surgical procedure or medical induction for the early second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.
After the completion of the surgical procedure or medical induction for the early second-trimester abortion or fetal loss, the participant will be administered a placebo pill orally with juice or water by the clinician or study investigator.
Cabergoline is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:
- Hyperprolactinemia
- Parkinsonian Syndrome
- Hyperprolactinemia
- Parkinsonian Syndrome
- Hyperprolactinemia
- Parkinsonian Syndrome
- Hyperprolactinemia
- Parkinsonian Syndrome
- Hyperprolactinemia
- Parkinsonian Syndrome
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
Planned Parenthood Mar Monte
Collaborator
Published Research Related to This Trial
Citations
Is Cabergoline Safe and Effective for Postpartum Lactation ...
Cabergoline is non-inferior to bromocriptine for lactation inhibition while also associated with fewer rebound symptoms and adverse effects.
Cabergoline: a review of its use in the inhibition of lactation ...
Cabergoline is at least as effective as bromocriptine for lactation inhibition with success rates between 78% and 100%. Transient, mild to moderate adverse ...
The efficiency of cabergoline vs pyridoxine for lactation ...
Cabergoline was superior to pyridoxine in inhibiting lactation. Cabergoline had more adverse effects, but no major adverse effect was documented in both ...
A Reduced Dose of Cabergoline for Lactation Inhibition ...
Recently, our own research found a single dose of cabergoline 1 mg effectively prevents breast symptoms after a second-trimester abortion or ...
Dostinex Tablets (Cabergoline)
In controlled clinical trials, DOSTINEX given as a single 1 mg administration during the first day post-partum, was effective in inhibiting milk secretion, ...
Cabergoline - Drugs and Lactation Database (LactMed®) - NCBI
Cabergoline was generally well tolerated for use in suppressing lactation, but dizziness, headache, nausea and vomiting occur occasionally.
DOSTINEX (cabergoline) tablets, for oral use
Avoid use of DOSTINEX for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions. Use of ...
Cabergoline Safety for Lactation Suppression
This systematic review demonstrates that adverse events were generally benign and tolerable following the administration of cabergoline.
Safety of Cabergoline for Postpartum Lactation Inhibition or ...
In conclusion, this systematic review demonstrates that adverse events were generally benign and tolerable following the administration of cabergoline. However, ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.